Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject CagriSema: Sites, Syringes and Steps

Where to inject CagriSema, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingAmylin + GLP-1 combinationUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for CagriSema in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

How the trials gave CagriSema

The REDEFINE 5 trial in Japan and Taiwan gave both drugs as once-weekly subcutaneous injections, escalated to 2.4 mg.[8]

REIMAGINE 3 added the combination to once-daily basal insulin and used identical-looking injections for active and placebo groups.[9]

REIMAGINE 1 states that all participants received visually identical injections to keep the study masked.[10]

The REDEFINE 1 secondary analyses describe the regimen as once-weekly CagriSema at 2.4 mg/2.4 mg.[11]

One fixed-dose combination

The REIMAGINE 2 abstract calls the product a fixed-dose combination of cagrilintide and semaglutide.[12]

The phase 1b trial instead gave cagrilintide and semaglutide 2.4 mg as separate once-weekly subcutaneous injections, without lifestyle interventions.[13]

Injection-site findings

A meta-analysis found the combination increased administration-site conditions compared with semaglutide, with a risk ratio of 3.27.[14]

No label to follow

The Drugs@FDA lookup of 2026-10-02 found no cagrisema product, so there are no labelled pen, site-rotation or storage instructions.[15]

Common questions

Where do you inject CagriSema?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for CagriSema?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is CagriSema injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

More on CagriSema

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.Legal statusFDA, compounding and WADA status with dates.For weight lossWhat research says about CagriSema for weight loss.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: cagrilintide[tiab] OR cagrisema[tiab] OR "cagrilintide and semaglutide"[tiab] (118 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: REDEFINE[tiab] AND (cagrilintide[tiab] OR semaglutide[tiab] OR CagriSema[tiab]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: cagrilintide[tiab] AND semaglutide[tiab] AND "Randomized Controlled Trial"[pt] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (cagrilintide[tiab] OR cagrisema[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
  9. 9Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026
  10. 10Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
  11. 11CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
  12. 12Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026PMID 42251859Accessed 2 Oct 2026
  13. 13Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  14. 14Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes, obesity & metabolism · 2026PMID 41834765Accessed 2 Oct 2026
  15. 15Drugs@FDA (openFDA) search: active ingredient "cagrisema"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.